Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs
Executive Summary
The catastrophic coverage provided under the Medicare Part D benefit may give private plan sponsors little incentive to control use of high-cost drugs, American Enterprise Institute Resident Fellow Scott Gottlieb said April 27
You may also be interested in...
Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade
Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade
Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap
Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."